Hong Huangming, Fang Xiaojie, Wang Zhao, Huang He, Lam Sio Teng, Li Fangfang, Peng Chen, Tian Ying, Lin Suxia, Lin Tongyu
a Department of Medical Oncology, Sun Yat-sen University Cancer Center , State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine , Guangzhou , China.
b Centro Hospitalar Conde de Sao Januario , Macau , China.
Leuk Lymphoma. 2018 Dec;59(12):2911-2916. doi: 10.1080/10428194.2018.1459610. Epub 2018 Jun 18.
Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of peripheral T-cell lymphoma with unique clinical and pathological features. This study aim to design a prognostic model specifically for AITL, providing risk stratification in affected patients. A total of 115 newly diagnosed AITL patients were retrospectively analyzed. The estimated five-year overall survival (OS) rate for all patients was 45.4%. Multivariate analysis found prognostic factors for survival were bone marrow involvement, number of extranodal sites >1, and performance status >1. We categorized three risk groups: group 1, no adverse factor; group 2, one factor; and group 3, two or three factors. Five-year OS was 86.9% for Group 1, 46.3% for Group 2, and 16.2% for Group 3 (p < .0001). The novel prognostic model balanced the distribution of patients into different risk groups with better predictive discrimination as compared to the International Prognostic Index and Prognostic Index for PTCL, unless otherwise specified.
血管免疫母细胞性T细胞淋巴瘤(AITL)是外周T细胞淋巴瘤的一种独特亚型,具有独特的临床和病理特征。本研究旨在设计一种专门针对AITL的预后模型,为受影响患者提供风险分层。对115例新诊断的AITL患者进行了回顾性分析。所有患者的估计五年总生存率(OS)为45.4%。多变量分析发现生存的预后因素为骨髓受累、结外部位数量>1和体能状态>1。我们将患者分为三个风险组:第1组,无不良因素;第2组,一个因素;第3组,两个或三个因素。第1组的五年OS为86.9%,第2组为46.3%,第3组为16.2%(p<0.0001)。与国际预后指数和外周T细胞淋巴瘤预后指数相比,除非另有说明,该新型预后模型能更好地将患者分配到不同风险组中,并具有更好的预测辨别力。